Effects of Baclofen on Presynaptic Inhibition in Humans

• Status: Recruiting
• Trial end date: 2021-01-10
• Target enrollment: 0
• Participant gender: All

Summary

This study examines the role of the GABA-B receptor in long-lasting presynaptic inhibition of primary afferents in human participants. Participants will come in for two visits, receiving baclofen (a GABA-B receptor agonist) on one visit and a placebo during the other. Electro-physiological measures will be use during both visit to asses presynaptic inhibition.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Alberta
• Treatments: Baclofen

Criteria

Inclusion Criteria:

• Healthy adults between the ages of 18 and 65 years.

• General good health

Exclusion Criteria:

• Contraindications to baclofen such as a known hypersensitivity to baclofen, renal impairment, stroke, epilepsy, pregnancy and lactation.

• Injury to peripheral nerves or muscles. Injury to nerves or muscles will confound the interpretation of the spinal reflex data.

• Participants with spinal cord injury already taking oral baclofen to manage spasticity.